Bionovo Announces First Quarter 2009 Highlights and Financi...(ables on Following Pages ...),Health

                                   Bionovo, Inc.
                          (A Development Stage Company)
                   Condensed Consolidated Statements of Operations
                 (Unaudited, in thousands, except per share amounts)

                                                                  Accumulated
                                                                from February
                                                             1, 2002 (Date of
                                         Three months ended     inception) to
                                              March 31,            March 31,
                                           2009        2008            2009

    Revenues                                $ -         $ -         $   892

    Operating expenses:
      Research and development            3,601       2,387          30,809
      General and administrative          1,009       1,822          14,558
      Merger cost                             -           -           1,964
    Total operating expenses              4,610       4,209          47,331

    Loss from operations                 (4,610)     (4,209)        (46,439)

      Change in fair value of
        warrant liability                     -           -             831
      Interest income                        54         306           2,045
      Interest expense                      (33)        (27)           (399)
      Other expense                         (79)        (19)           (156)
    Net loss                            $(4,668)    $(3,949)       $(44,118)
      Basic and diluted net loss
        per common share                 $(0.06)     $(0.05)         $(1.02)

      Shares used in computing basic
        and diluted net loss per share   76,363      76,343          43,280

                                  Bionovo, Inc.
                    
'/>"/>
SOURCE  Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 
Related medicine technology :

1. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
2. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
3. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
4. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
5. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
8. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
9. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
10. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
11. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial